MRS 2578 50 mg | Purity Not Available
TargetMol
MRS2578, an effective P2Y6 receptor antagonist with IC50 of 37 nM, shows insignificant inhibition at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
More Information Supplier PageMRS 2578
Search Results
Mirdametinib 25 mg | 99.91%
TargetMol
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier PageMirdametinib
Mirdametinib 50 mg | 99.91%
TargetMol
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier PageMirdametinib
PP1 2 mg | 99.82%
TargetMol
PP1, a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
More Information Supplier PagePP1
PP1 25 mg | 99.82%
TargetMol
PP1, a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
More Information Supplier PagePP1
Tasisulam 5 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Tasisulam 50 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Tasisulam 25 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Tasisulam 10 mg | 99.97%
TargetMol
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
More Information Supplier PageTasisulam
Mirdametinib 5 mg | 99.91%
TargetMol
PD0325901 is a specific and non-ATP-competitive MEK inhibitor (IC50: 0.33 nM).
More Information Supplier PageMirdametinib